WHO Drug Information Vol. 15, No. 3 & 4, 2001
(2001; 76 pages) Voir le document au format PDF
Table des matières
Afficher le documentWHO Drug Information
Ouvrir ce répertoire et afficher son contenuPersonal Perspectives
Ouvrir ce répertoire et afficher son contenuReports on Individual Drugs
Ouvrir ce répertoire et afficher son contenuQuality Assurance Issues
Ouvrir ce répertoire et afficher son contenuCurrent Topics
Ouvrir ce répertoire et afficher son contenuGeneral Information
Fermer ce répertoireRegulatory and Safety Matters*
Afficher le documentInfliximab and congestive heart failure
Afficher le documentInfliximab: warning of opportunistic infections
Afficher le documentBrimonidine ophthalmic drops: accidental ingestion
Afficher le documentP-Glycoprotein and drug interaction
Afficher le documentNonacog alfa: intensive surveillance
Afficher le documentTenofovir disoproxil fumarate approved for HIV infection
Afficher le documentCiprofloxacin hydrochloride for inhalation anthrax
Afficher le documentDTPa and limb swelling
Afficher le documentNitrofurantoin and peripheral neuropathy
Afficher le documentContinued suspension for tolcapone
Afficher le documentMMR vaccine and idiopathic thrombocytopenic purpura
Afficher le documentNew communications and networking unit at EMEA
Ouvrir ce répertoire et afficher son contenuATC/DDD Classification
Ouvrir ce répertoire et afficher son contenuRegulatory Information
Afficher le documentRecommended International Nonproprietary Names (rec. Inn): List 46
Afficher le documentSelected WHO Publications of Related Interest
 

Regulatory and Safety Matters*

* Spontaneous monitoring systems are useful in detecting signals of relatively rare, serious and unexpected adverse drug reactions. A signal is defined as “reported information on a possible causal relationship between an adverse event and a drug, the relationship being unknown or incompletely documented previously. Usually, more than a single report is required to generate a signal, depending upon the seriousness of the event and the quality of the information”. All signals must be validated before any regulatory decision can be made.

vers la section précédente vers la section suivante
 

Dernière mise à jour: le 24 avril 2012